Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy
Patrick Hamilton, Durga Kanigicherla, Prasanna Hanumapura, Lars Walz, Dieter Kramer, Moritz Fischer, Paul Brenchley, Sandip Mitra
Research output: Contribution to journal › Article › peer-review
127Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy'. Together they form a unique fingerprint.